Compare Lennar Corporation (LEN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Repligen Corporation Common Stock — how do they compare? Lennar Corporation trades at $74.73 (market cap $17.81B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Lennar Corporation is the larger of the two by market cap, and Lennar Corporation pays a 2.67% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Repligen Corporation Common Stock for 0 Days on average.
| LEN | RGEN | |
|---|---|---|
Market Cap | $17.81B | $11.14B |
Volume | 4,102,017 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $194.57 |
52-Week Low | $73.53 | $102.87 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $22.23B | $11.02B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar Corporation (LEN) trades at $74.92, showing modest daily gains but facing bearish technical signals with recent earnings misses. The stock trades below book value (P/B 0.83) with reasonable P/E of 14.19, while revenue declined to $34.19B in 2025 with net income margin compressing to 6.07%. Berkshire Hathaway's significant stake accumulation to 11.2% provides institutional support despite recent negative news flow.
The outlook remains challenged by housing market headwinds and margin pressure, but deep value characteristics and Berkshire's backing offer potential upside to the $77.38 consensus target. Key risks include persistent earnings misses, rising mortgage rates, and the Hunterbrook short report allegations regarding Millrose transactions.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
